Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons

Taishiro Kishimoto, Katsuhiko Hagi, Masahiro Nitta, John M. Kane, Christoph U. Correll

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Second-generation antipsychotics (SGAs) are recommended for maintenance treatment in schizophrenia. However, comparative long-term effectiveness among SGAs is unclear. Here we provide a systematic review and meta-analysis of randomized trials lasting ≥⃒6 months comparing SGAs head-to-head in schizophrenia and related disorders. The primary outcome was all-cause discontinuation. Secondary outcomes included efficacy and tolerability, i.e., psychopathology, inefficacy-related and intolerability-related discontinuation, relapse, hospitalization, remission, functioning, quality of life, and adverse events. Pooled risk ratio and standardized mean difference were calculated using random-effects models. Across 59 studies (N=45,787), lasting 47.4±32.1 weeks (range 24-186), no consistent superiority of any SGA emerged across efficacy and tolerability outcomes. Regarding all-cause discontinuation, clozapine, olanzapine and risperidone were significantly (p<0.05) superior to several other SGAs, while quetiapine was inferior to several other SGAs. As to psychopathology, clozapine and olanzapine were superior to several other SGAs, while quetiapine and ziprasidone were inferior to several other SGAs. Data for other efficacy outcomes were sparse. Regarding intolerability-related discontinuation, risperidone was superior and clozapine was inferior to several other SGAs. Concerning weight gain, olanzapine was worse than all other compared non-clozapine SGAs, and risperidone was significantly worse than several other SGAs. As to prolactin increase, risperidone and amisulpride were significantly worse than several other SGAs. Regarding parkinsonism, olanzapine was superior to risperidone, without significant differences pertaining to akathisia. Concerning sedation and somnolence, clozapine and quetiapine were significantly worse than some other SGAs. In summary, different long-term SGA efficacy and tolerability patterns emerged. The long-term risk-benefit profiles of specific SGAs need to be tailored to individual patients to optimize maintenance treatment outcomes.

Original languageEnglish
Pages (from-to)208-224
Number of pages17
JournalWorld Psychiatry
Volume18
Issue number2
DOIs
Publication statusPublished - 2019 Jun 1

Fingerprint

Antipsychotic Agents
Meta-Analysis
Schizophrenia
olanzapine
Risperidone
Clozapine
Psychopathology
Psychomotor Agitation
Parkinsonian Disorders
Prolactin
Weight Gain
Hospitalization
Odds Ratio
Quality of Life

Keywords

  • clozapine
  • efficacy
  • maintenance treatment
  • olanzapine
  • randomized controlled trials
  • risperidone
  • Second-generation antipsychotics
  • tolerability
  • treatment discontinuation

ASJC Scopus subject areas

  • Phychiatric Mental Health
  • Psychiatry and Mental health

Cite this

Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders : a systematic review and meta-analysis of direct head-to-head comparisons. / Kishimoto, Taishiro; Hagi, Katsuhiko; Nitta, Masahiro; Kane, John M.; Correll, Christoph U.

In: World Psychiatry, Vol. 18, No. 2, 01.06.2019, p. 208-224.

Research output: Contribution to journalReview article

@article{7d9fbd1f6934442989d572e81018ebaa,
title = "Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons",
abstract = "Second-generation antipsychotics (SGAs) are recommended for maintenance treatment in schizophrenia. However, comparative long-term effectiveness among SGAs is unclear. Here we provide a systematic review and meta-analysis of randomized trials lasting ≥⃒6 months comparing SGAs head-to-head in schizophrenia and related disorders. The primary outcome was all-cause discontinuation. Secondary outcomes included efficacy and tolerability, i.e., psychopathology, inefficacy-related and intolerability-related discontinuation, relapse, hospitalization, remission, functioning, quality of life, and adverse events. Pooled risk ratio and standardized mean difference were calculated using random-effects models. Across 59 studies (N=45,787), lasting 47.4±32.1 weeks (range 24-186), no consistent superiority of any SGA emerged across efficacy and tolerability outcomes. Regarding all-cause discontinuation, clozapine, olanzapine and risperidone were significantly (p<0.05) superior to several other SGAs, while quetiapine was inferior to several other SGAs. As to psychopathology, clozapine and olanzapine were superior to several other SGAs, while quetiapine and ziprasidone were inferior to several other SGAs. Data for other efficacy outcomes were sparse. Regarding intolerability-related discontinuation, risperidone was superior and clozapine was inferior to several other SGAs. Concerning weight gain, olanzapine was worse than all other compared non-clozapine SGAs, and risperidone was significantly worse than several other SGAs. As to prolactin increase, risperidone and amisulpride were significantly worse than several other SGAs. Regarding parkinsonism, olanzapine was superior to risperidone, without significant differences pertaining to akathisia. Concerning sedation and somnolence, clozapine and quetiapine were significantly worse than some other SGAs. In summary, different long-term SGA efficacy and tolerability patterns emerged. The long-term risk-benefit profiles of specific SGAs need to be tailored to individual patients to optimize maintenance treatment outcomes.",
keywords = "clozapine, efficacy, maintenance treatment, olanzapine, randomized controlled trials, risperidone, Second-generation antipsychotics, tolerability, treatment discontinuation",
author = "Taishiro Kishimoto and Katsuhiko Hagi and Masahiro Nitta and Kane, {John M.} and Correll, {Christoph U.}",
year = "2019",
month = "6",
day = "1",
doi = "10.1002/wps.20632",
language = "English",
volume = "18",
pages = "208--224",
journal = "World Psychiatry",
issn = "1723-8617",
publisher = "Masson SpA",
number = "2",

}

TY - JOUR

T1 - Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders

T2 - a systematic review and meta-analysis of direct head-to-head comparisons

AU - Kishimoto, Taishiro

AU - Hagi, Katsuhiko

AU - Nitta, Masahiro

AU - Kane, John M.

AU - Correll, Christoph U.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Second-generation antipsychotics (SGAs) are recommended for maintenance treatment in schizophrenia. However, comparative long-term effectiveness among SGAs is unclear. Here we provide a systematic review and meta-analysis of randomized trials lasting ≥⃒6 months comparing SGAs head-to-head in schizophrenia and related disorders. The primary outcome was all-cause discontinuation. Secondary outcomes included efficacy and tolerability, i.e., psychopathology, inefficacy-related and intolerability-related discontinuation, relapse, hospitalization, remission, functioning, quality of life, and adverse events. Pooled risk ratio and standardized mean difference were calculated using random-effects models. Across 59 studies (N=45,787), lasting 47.4±32.1 weeks (range 24-186), no consistent superiority of any SGA emerged across efficacy and tolerability outcomes. Regarding all-cause discontinuation, clozapine, olanzapine and risperidone were significantly (p<0.05) superior to several other SGAs, while quetiapine was inferior to several other SGAs. As to psychopathology, clozapine and olanzapine were superior to several other SGAs, while quetiapine and ziprasidone were inferior to several other SGAs. Data for other efficacy outcomes were sparse. Regarding intolerability-related discontinuation, risperidone was superior and clozapine was inferior to several other SGAs. Concerning weight gain, olanzapine was worse than all other compared non-clozapine SGAs, and risperidone was significantly worse than several other SGAs. As to prolactin increase, risperidone and amisulpride were significantly worse than several other SGAs. Regarding parkinsonism, olanzapine was superior to risperidone, without significant differences pertaining to akathisia. Concerning sedation and somnolence, clozapine and quetiapine were significantly worse than some other SGAs. In summary, different long-term SGA efficacy and tolerability patterns emerged. The long-term risk-benefit profiles of specific SGAs need to be tailored to individual patients to optimize maintenance treatment outcomes.

AB - Second-generation antipsychotics (SGAs) are recommended for maintenance treatment in schizophrenia. However, comparative long-term effectiveness among SGAs is unclear. Here we provide a systematic review and meta-analysis of randomized trials lasting ≥⃒6 months comparing SGAs head-to-head in schizophrenia and related disorders. The primary outcome was all-cause discontinuation. Secondary outcomes included efficacy and tolerability, i.e., psychopathology, inefficacy-related and intolerability-related discontinuation, relapse, hospitalization, remission, functioning, quality of life, and adverse events. Pooled risk ratio and standardized mean difference were calculated using random-effects models. Across 59 studies (N=45,787), lasting 47.4±32.1 weeks (range 24-186), no consistent superiority of any SGA emerged across efficacy and tolerability outcomes. Regarding all-cause discontinuation, clozapine, olanzapine and risperidone were significantly (p<0.05) superior to several other SGAs, while quetiapine was inferior to several other SGAs. As to psychopathology, clozapine and olanzapine were superior to several other SGAs, while quetiapine and ziprasidone were inferior to several other SGAs. Data for other efficacy outcomes were sparse. Regarding intolerability-related discontinuation, risperidone was superior and clozapine was inferior to several other SGAs. Concerning weight gain, olanzapine was worse than all other compared non-clozapine SGAs, and risperidone was significantly worse than several other SGAs. As to prolactin increase, risperidone and amisulpride were significantly worse than several other SGAs. Regarding parkinsonism, olanzapine was superior to risperidone, without significant differences pertaining to akathisia. Concerning sedation and somnolence, clozapine and quetiapine were significantly worse than some other SGAs. In summary, different long-term SGA efficacy and tolerability patterns emerged. The long-term risk-benefit profiles of specific SGAs need to be tailored to individual patients to optimize maintenance treatment outcomes.

KW - clozapine

KW - efficacy

KW - maintenance treatment

KW - olanzapine

KW - randomized controlled trials

KW - risperidone

KW - Second-generation antipsychotics

KW - tolerability

KW - treatment discontinuation

UR - http://www.scopus.com/inward/record.url?scp=85065392416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065392416&partnerID=8YFLogxK

U2 - 10.1002/wps.20632

DO - 10.1002/wps.20632

M3 - Review article

AN - SCOPUS:85065392416

VL - 18

SP - 208

EP - 224

JO - World Psychiatry

JF - World Psychiatry

SN - 1723-8617

IS - 2

ER -